Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Tadalafil can lower blood pressure in women, and while most healthy users experience only mild effects like flushing, headache, or dizziness, the drop can become dangerous when combined with nitrates, certain alpha-blockers, or other blood pressure medications. Women with unstable angina, recent heart attack or stroke, severe heart failure, uncontrolled hypertension, or very low baseline blood pressure face the highest risk of fainting, chest pain, or serious cardiovascular events. Rare but serious concerns include irregular heartbeat, sudden vision or hearing loss, and prolonged low blood pressure requiring emergency care. Because tadalafil is not FDA-approved for female sexual dysfunction, safety data in women remains limited, making individual risk factors especially important to review. There are several factors to consider, including drug interactions and warning signs to watch for, so see below to understand more.
If you are noticing dizziness, palpitations, chest discomfort, or unusual fatigue and are unsure whether a medication, your heart, or something else is behind it, guessing is the riskiest option. A free, instant, online symptom check takes just a few minutes, asks the same kinds of questions a clinician would, and helps you understand which possibilities fit your situation and how urgently you should act. It costs nothing, requires no appointment, and can help you walk into a pharmacy or doctor's office knowing exactly what to ask, which is far better than waiting to see if symptoms pass on their own.
Last reviewed for medical accuracy: 09/13/2026
Can tadalafil cause dangerous heart or blood pressure problems in women?
Tadalafil (Cialis®) is a phosphodiesterase-5 (PDE5) inhibitor widely known for treating erectile dysfunction in men. In women, it’s used off-label for conditions like female sexual arousal disorder and approved for pulmonary arterial hypertension (PAH). Because tadalafil works by widening blood vessels and lowering blood pressure, it’s natural to wonder whether it might pose cardiovascular risks—especially in women. Below, we’ll review what the evidence tells us, outline possible issues, and offer practical advice.
Tadalafil blocks the PDE5 enzyme, which normally breaks down cyclic guanosine monophosphate (cGMP). Higher cGMP levels in blood vessel walls lead to relaxation of smooth muscle and increased blood flow. In pulmonary hypertension, this eases pressure in the lungs; in sexual arousal it may enhance genital blood flow.
Key effects on the cardiovascular system:
Because tadalafil lowers vascular resistance, blood pressure (BP) can drop by 5–10 mmHg on average. In most healthy adults, this is well tolerated. However, certain situations can amplify the effect:
Women with any of these factors need careful evaluation before using tadalafil.
Though uncommon, tadalafil may trigger or unmask cardiac issues:
Tadalafil is generally safe for women without cardiovascular disease, but extra caution is needed if you have:
Stop tadalafil and seek medical help if you experience:
These symptoms may indicate dangerously low blood pressure, heart ischemia, or an arrhythmia.
Clinical trials in PAH patients (including women) show tadalafil is generally well tolerated:
Data on sexual function in women are less robust, but adverse event profiles mirror those in male studies.
Before starting tadalafil, discuss these points with your doctor:
In addition to medication, maintaining heart health is key:
Never ignore symptoms that could signal serious issues. If you’re unsure whether your symptoms are medication-related or life-threatening, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. If you have chest pain, prolonged fainting, sudden vision changes or persistent palpitations, call emergency services immediately.
Speak to your doctor before starting or changing tadalafil. Only they can determine your personal risk and ensure safe use. If you experience any concerning symptoms—or simply want guidance—schedule an appointment promptly. Your health and safety come first.
(References)
* Khera M, Goldstein I. Erectile dysfunction. BMJ Clin Evid. 2011 Jun 29;2011. Epub 2011 Jun 29. PMID: 21711956; PMCID: PMC3217797.
* Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. PMID: 26308684.
* Yamamura A, Fujitomi E, Ohara N, Tsukamoto K, Sato M, Yamamura H. Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. Eur J Pharmacol. 2017 Sep 5;810:44-50. doi: 10.1016/j.ejphar.2017.06.010. Epub 2017 Jun 8. PMID: 28603047.
* Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. PMID: 35412560.
* Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024 Jan 30;83(4):473-484. doi: 10.1016/j.jacc.2023.10.045. PMID: 38267108.
* Hoeper MM, Oerke B, Wissmüller M, Leuchte H, Opitz C, Halank M, Seyfarth HJ, Baldus S, Bauersachs J, Böhm M, Ghofrani HA, Konstantinides S, Olsson KM, Wachter R, Lam CSP, Aminossadati B, Rosenkranz S. Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study. Circulation. 2024 Aug 20;150(8):600-610. doi: 10.1161/CIRCULATIONAHA.124.069340. Epub 2024 Jun 28. PMID: 38939948.
* McLaughlin VV, Sitbon O, Chin KM, Galiè N, Hoeper MM, Kiely DG, MacDonald G, Martin N, Mathai SC, Peacock A, Tawakol A, Torbicki A, Vonk Noordegraaf A, Rosenkranz S. Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. Eur J Heart Fail. 2024 Nov;26(11):2379-2391. doi: 10.1002/ejhf.3319. Epub 2024 Jul 5. PMID: 38966990; PMCID: PMC11659495.
* Jehle DVK, Sunesra R, Uddin H, Paul KK, Joglar AA, Michler OD, Blackwell TA, Gaalema D, Hayek S, Jneid H. Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia. Am J Med. 2025 Mar;138(3):441-448.e3. doi: 10.1016/j.amjmed.2024.10.039. Epub 2024 Nov 10. PMID: 39532245.
* Ölmestig J, Mortensen KN, Thomas MB, Fagerlund B, Naveed N, Nordling MM, Nielsen MKK, Rasmussen BS, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke. 2025 Oct;56(10):2846-2857. doi: 10.1161/STROKEAHA.125.051602. Epub 2025 Jul 28. PMID: 40718899; PMCID: PMC12447817.
* Li Z, Liu A, Qian A, Feng W, Yang J, Tian X, Zhao Z, Zhou S, Zhao AZ, Mu Y, Li F. Tadalafil protects against renal fibrosis after ischemia-reperfusion injury by inhibiting Akt/NF-κB signaling pathway. Eur J Pharmacol. 2025 Dec 15;1009:178388. doi: 10.1016/j.ejphar.2025.178388. Epub 2025 Nov 19. PMID: 41271150.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.